(ASTH) Astrana Health - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03763A2078
ASTH: Care Coordination, Medical Services, Healthcare Management
Astrana Health Inc. (NASDAQ: ASTH) stands as a beacon in the healthcare sector, championing a physician-centric, technology-driven approach. This model not only empowers healthcare providers but also integrates advanced data analytics to enhance patient outcomes, reflecting the broader shift towards value-based care. Their three core segments—Care Partners, Care Delivery, and Care Enablement—work in harmony to offer comprehensive care coordination, ensuring seamless communication between patients, families, and healthcare providers.
The companys value-based model is underpinned by a proprietary platform that leverages population health management. This platform is pivotal in optimizing care delivery, making it both efficient and cost-effective. By focusing on patient outcomes rather than traditional fee-for-service models, Astrana Health aligns with the growing trend of prioritizing quality over quantity in healthcare. This strategic focus positions them well in a sector increasingly demanding better value for each dollar spent.
Astrana Healths extensive network includes primary care physicians, specialists, and hospitalists, serving a diverse patient base covered by various insurance plans, including Medicare, Medicaid, and HMOs, as well as self-pay individuals. This broad reach underscores their commitment to accessible care. Their recent rebranding from Apollo Medical Holdings to Astrana Health in February 2024 may signal a strategic shift, possibly indicating an expanded scope or a renewed focus on innovation.
From a financial standpoint, Astrana Health presents an intriguing profile for investors. With a market capitalization of approximately $1.633 billion, the companys P/E ratio of 27.31 suggests high growth expectations. The forward P/E of 21.69 indicates anticipated earnings growth, aligning with the potential of their value-based model. The P/B ratio of 2.32 highlights the markets confidence in their intangible assets, such as their technology platform, while the P/S ratio of 0.95 reflects a reasonable valuation relative to revenue.
Additional Sources for ASTH Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ASTH Stock Overview
Market Cap in USD | 1,397m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2000-01-13 |
ASTH Stock Ratings
Growth 5y | 40.4% |
Fundamental | 36.2% |
Dividend | 0.0% |
Rel. Strength Industry | -27.5 |
Analysts | 4.67/5 |
Fair Price Momentum | 28.46 USD |
Fair Price DCF | 29.60 USD |
ASTH Dividends
No Dividends PaidASTH Growth Ratios
Growth Correlation 3m | -21.8% |
Growth Correlation 12m | -25.4% |
Growth Correlation 5y | 39% |
CAGR 5y | 25.12% |
CAGR/Max DD 5y | 0.32 |
Sharpe Ratio 12m | 0.15 |
Alpha | -38.60 |
Beta | 1.17 |
Volatility | 78.77% |
Current Volume | 338.6k |
Average Volume 20d | 328.4k |
As of March 15, 2025, the stock is trading at USD 29.34 with a total of 338,595 shares traded.
Over the past week, the price has changed by -0.14%, over one month by -24.69%, over three months by -20.27% and over the past year by -26.81%.
Partly, yes. Based on ValueRay Fundamental Analyses, Astrana Health (NASDAQ:ASTH) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 36.20 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ASTH as of March 2025 is 28.46. This means that ASTH is currently overvalued and has a potential downside of -3%.
Astrana Health has received a consensus analysts rating of 4.67. Therefor, it is recommend to buy ASTH.
- Strong Buy: 10
- Buy: 0
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ASTH Astrana Health will be worth about 31.2 in March 2026. The stock is currently trading at 29.34. This means that the stock has a potential upside of +6.37%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 52.3 | 78.3% |
Analysts Target Price | 63.6 | 116.8% |
ValueRay Target Price | 31.2 | 6.4% |